Drug Patents owned by Almirall

1. List of Aczone drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9161926 ALMIRALL Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Nov, 2033

(10 years from now)

US9517219 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(10 years from now)

US11273132 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Sep 10, 2022

Drugs and Companies using DAPSONE ingredient

Market Authorisation Date: 24 February, 2016

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

How can I launch a generic of ACZONE before it's patent expiration?
More Information on Dosage

2. List of Altabax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191 ALMIRALL Process, salts, composition and use
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage

3. List of Klisyri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(2 years from now)

US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(2 years from now)

US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(3 years from now)

US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(6 years from now)

US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof
Dec, 2027

(4 years from now)

US11497750 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(15 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage

4. List of Seysara drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8318706 ALMIRALL Substituted tetracycline compounds
May, 2031

(8 years from now)

US9255068 ALMIRALL Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Feb, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9481639 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders
Aug, 2028

(5 years from now)

US8513223 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders
Dec, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 1, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses; A method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride; A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride; A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt; A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Verdeso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(2 years from now)

US8962000 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(2 years from now)

US8460641 ALMIRALL Microemulsion process and composition
Aug, 2027

(4 years from now)

Drugs and Companies using DESONIDE ingredient

Market Authorisation Date: 19 September, 2006

Treatment: Treatment of atopic dermatitis

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic